Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*

Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*

Once-daily oral XOCOVA is now available by prescription for adults and adolescents 12 years of age and older1

In a global clinical trial, XOCOVA significantly reduced the risk of symptomatic COVID-19 by 67% following exposure to an infected individual, compared to placebo2

XOCOVA availability comes ahead of an anticipated summer surge in COVID-19 cases3

Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced U.S. availability of XOCOVA® (ensitrelvir), an oral antiviral, approved for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.2